ASX Health Stocks: RAC says combining lead drug bisantrene with...

ASX Health Stocks: RAC says combining lead drug bisantrene with decitabine is effective on solid tumours

Race Oncology says bisantrene + decitabine effective

Race Oncology (ASX:RAC) jumped 8% this morning after sharing the results from recent preclinical studies conducted at Oncolines B.V. in the Netherlands.

In these studies, bisantrene (Race’s lead drug) was tested in combination with decitabine to enhance anticancer activity.

Results showed that bisantrene and decitabine used together have significantly improved cancer cell-killing across 143 tumour cell lines, than either drug used alone.

Combining these two drugs at clinical doses significantly boosted cancer cell-killing, with 92% (131 out of 143) of the cell lines showing improvement.

These results suggest that the combination could be a promising treatment for various cancers, including solid tumors like lung, prostate, pancreas, breast, and head and neck cancer.

Decitabine is an FDA-approved drug widely used to treat certain blood cancers like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), but it hasn’t been effective against solid tumours.

However, this study found that decitabine boosts the cancer cell-killing power of bisantrene across a wide range of common human cancers, including many solid tumours.

Race says it will now continue to critically evaluate all opportunities in this space from both a commercial and scientific perspective.

https:// *. com. au/health/asx-health-stocks-rac-says-combining-lead-drug-bisantrene-with-decitabine-is-effective-on-solid-tumours/

“These results open exciting new treatment opportunities for both bisantrene and decitabine,” said Race’s CEO, Dr Daniel Tillett.